Diagnostic Value of MIBG Cardiac Scintigraphy for Differential Dementia Diagnosis

Overview

Journal Int J Geriatr Psychiatry

Specialties Geriatrics
Psychiatry

Date 2014 Nov 4

PMID 25363642

Citations 12

Authors

Sylvie Slaets

Frank Van Acker

Jan Versijpt

Lothar Hauth

Johan Goeman

Jean-Jacques Martin

Peter Paul De Deyn

Sebastiaan Engelborghs

Affiliations

Soon will be listed here.

Abstract

Objective: Iodine-123 metaiodobenzylguanidine (MIBG) cardiac scintigraphy has shown the potential to discriminate dementia with Lewy bodies (DLB) from Alzheimer's disease (AD). However, these studies did not reflect clinical practice, as patients with ischemic heart disease, heart failure, diabetes mellitus, arterial hypertension, and hyperlipidemia and patients treated with antidepressants like trazodone were excluded.

Methods: This study aimed to evaluate the use of MIBG cardiac scintigraphy to diagnose DLB in clinical practice. Moreover, the potential diagnostic value of MIBG cardiac scintigraphy in patients with clinically ambiguous dementia diagnosis (DLB versus AD) was tested. Eighty-five patients with a possible clinical diagnosis of DLB entered the study. MIBG uptake was determined by calculating the heart-to-mediastinum-uptake ratio (H/M).

Results: The average H/M ratio was 1.42 ± 0.35. The number of core features for DLB and the H/M ratio were negatively correlated (p = 0.001; r = -0.360). With an H/M ratio cutoff of 1.68 in 20 patients with clinically ambiguous dementia diagnoses (DLB versus AD) at the moment of MIBG cardiac scintigraphy, 95% (19/20) of the patients were correctly classified as compared with clinical or definite diagnosis at follow-up, with sensitivity and specificity values for diagnosing DLB of 100% (16/16) and 75% (3/4), respectively. The H/M ratio was influenced only by age (p = 0.046; r = -0.217) and gender (p = 0.024) and not by any other variable studied.

Conclusions: The MIBG cardiac scintigraphy H/M ratio is a possible diagnostic biomarker for DLB in routine clinical practice and might have an added diagnostic value in case of doubt between DLB and AD.

Citing Articles

Atypical Parkinsonian Syndromes: Structural, Functional, and Molecular Imaging Features.

Keir G, Roytman M, Mashriqi F, Shahsavarani S, Franceschi A AJNR Am J Neuroradiol. 2024; 45(12):1865-1877.

PMID: 39209485 PMC: 11630880. DOI: 10.3174/ajnr.A8313.

Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.

Higuchi T, Chen X, Werner R Theranostics. 2024; 14(8):3178-3192.

PMID: 38855189 PMC: 11155404. DOI: 10.7150/thno.96743.

Phantom-Based Standardization Method for I-metaiodobenzylguanidine Heart-to-Mediastinum Ratio Validated by D-SPECT Versus Anger Camera.

Yamashita S, Nakajima K, Okuda K, Yamamoto H, Shibutani T, Yoneyama T Ann Nucl Cardiol. 2023; 9(1):85-90.

PMID: 38058581 PMC: 10696155. DOI: 10.17996/anc.23-00003.

Optimal Protocol and Clinical Usefulness of I-MIBG Cardiac Scintigraphy for Differentiation of Parkinson's Disease and Dementia with Lewy Body from Non-Parkinson's Diseases.

Chun I Nucl Med Mol Imaging. 2023; 57(3):145-154.

PMID: 37187951 PMC: 10172433. DOI: 10.1007/s13139-023-00790-w.

The Noradrenergic System in Parkinson's Disease.

Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, De Deurwaerdere P, Miguelez C Front Pharmacol. 2020; 11:435.

PMID: 32322208 PMC: 7157437. DOI: 10.3389/fphar.2020.00435.

References

Wieland D, Wu J, Brown L, Mangner T, Swanson D, BEIERWALTES W . Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980; 21(4):349-53. View

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E . Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis. 2013; 35(1):137-46. DOI: 10.3233/JAD-122176. View

Estorch M, Camacho V, Paredes P, Rivera E, Rodriguez-Revuelto A, Flotats A . Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging. 2008; 35(9):1636-41. DOI: 10.1007/s00259-008-0828-8. View

Watanabe H, Ieda T, Katayama T, Takeda A, Aiba I, Doyu M . Cardiac (123)I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001; 70(6):781-3. PMC: 1737405. DOI: 10.1136/jnnp.70.6.781. View

Sakakibara R, Ogata T, Haruta M, Kishi M, Tsuyusaki Y, Tateno A . Amnestic mild cognitive impairment with low myocardial metaiodobenzylguanidine uptake. Am J Neurodegener Dis. 2013; 1(2):146-51. PMC: 3560457. View

Yoshita M, Taki J, Yamada M . A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001; 71(5):583-8. PMC: 1737586. DOI: 10.1136/jnnp.71.5.583. View

Mayer S, Karanikas G, Rodrigues M, Sinzinger H . Influence of drugs on myocardial iodine-123 metaiodobenzylguanidine uptake in rabbit myocardium. Eur J Nucl Med. 2000; 27(3):340-5. DOI: 10.1007/s002590050043. View

Sakata K, Iida K, Mochizuki N, Ito M, Nakaya Y . Physiological changes in human cardiac sympathetic innervation and activity assessed by (123)I-metaiodobenzylguanidine (MIGB) imaging. Circ J. 2008; 73(2):310-5. DOI: 10.1253/circj.cj-08-0614. View

10.

Hanyu H, Shimizu S, Hirao K, Sakurai H, Iwamoto T, Chikamori T . The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord. 2006; 22(5-6):379-84. DOI: 10.1159/000095641. View

11.

Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T . Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 2005; 109(6):583-8. DOI: 10.1007/s00401-005-0995-7. View

12.

Wada-Isoe K, Kitayama M, Nakaso K, Nakashima K . Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci. 2007; 260(1-2):33-7. DOI: 10.1016/j.jns.2007.03.016. View

13.

Solanki K, Bomanji J, Moyes J, Mather S, Trainer P, Britton K . A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992; 13(7):513-21. DOI: 10.1097/00006231-199207000-00006. View

14.

Kobayashi S, Tateno M, Morii H, Utsumi K, Saito T . Decreased cardiac MIBG uptake, its correlation with clinical symptoms in dementia with Lewy bodies. Psychiatry Res. 2009; 174(1):76-80. DOI: 10.1016/j.pscychresns.2009.02.006. View

15.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin J, Engelborghs S . Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. J Alzheimers Dis. 2012; 33(1):117-31. DOI: 10.3233/JAD-2012-121246. View

16.

Fujishiro H, Nakamura S, Kitazawa M, Sato K, Iseki E . Early detection of dementia with Lewy bodies in patients with amnestic mild cognitive impairment using 123I-MIBG cardiac scintigraphy. J Neurol Sci. 2011; 315(1-2):115-9. DOI: 10.1016/j.jns.2011.11.012. View

17.

Oide T, Tokuda T, Momose M, Oguchi K, Nakamura A, Ohara S . Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med. 2003; 42(8):686-90. DOI: 10.2169/internalmedicine.42.686. View

18.

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K . Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006; 112(4):389-404. PMC: 3906709. DOI: 10.1007/s00401-006-0127-z. View

19.

Merdes A, Hansen L, Jeste D, Galasko D, Hofstetter C, Ho G . Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003; 60(10):1586-90. DOI: 10.1212/01.wnl.0000065889.42856.f2. View

20.

McKeith I, Dickson D, Lowe J, Emre M, OBrien J, Feldman H . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65(12):1863-72. DOI: 10.1212/01.wnl.0000187889.17253.b1. View